featured
Degarelix in Prolonging the Off-Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent ADT for Biochemical Recurrence Following Radical Local Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Journal of Urology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase II, Randomized, Multicentre Study Comparing 10 Months Versus 4 Months of Degarelix (Firmagon®) Therapy in Prolonging the Off Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence Following Radical Local Therapy
J Urol 2018 Mar 10;[EPub Ahead of Print], L Klotz, A Loblaw, R Siemens, P Ouellette, A Kapoor, M Kebabdjian, L Zhang, F SaadFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.